VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon Sep 05, 2024 7:04am

128 Views

Post# 36209389

3mensio! 🔬maybe news Collaborations or Partnerships ? 🤔👀

Interesting Remenber Hugh in London maybe news Collaborations or Partnerships ? and remember post Hugh (On Linkedin Hugh MacNaught (Wednesday 28)This afternoon I am travelling to London for introductory meetings with potential collaborators and industry partners who are attending the 2024 ESC Congress. Rather than exhibiting at this year's congress we have arranged meetings to discuss specific opportunities and initiatives. With the introduction of magnet-free sensors, recent Health Canada Medical Device License for VMS+ V4.0 and approval/clearance pending in other key markets we are actively pursuing opportunities to deploy our products.)

New Research on CT-Based Planning for LAA Closure with 3mensio!

A recent study titled "Computed Tomography-Based Selection of Transseptal Puncture Site for Percutaneous LAA Closure" highlights how the 3mensio LAA planning tool helps determine the optimal transseptal puncture site by analyzing the spatial relationship between the LAA and the fossa ovalis.

3mensio's CT-based imaging enables precise angulation and distance measurements, offering tailored procedural planning for improved patient outcomes and safety.

Read the whole study here: https://lnkd.in/exzEdtZc

For more information on 3mensio LAA, feel free to reach out!

Stay tuned for more updates!

Angiopro 3mensio Cardiology MedicalImaging LAAClosure TransseptalPuncture CTImaging PatientCare